The Compound
What PT-141 Actually Is
2019
FDA Approval Year (Vyleesi)
~2.7 hr
Plasma Half-Life
40%
Nausea Incidence, Phase 3
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist. It is not a vasodilator like Viagra or Cialis. It works through an entirely different mechanism: activating melanocortin-4 receptors (MC4R) in the central nervous system to trigger sexual arousal pathways at the brain level, rather than producing genital vasodilation peripherally.
The branded version, Vyleesi, received FDA approval in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It was the first FDA-approved on-demand treatment for low sexual desire. Every other application of bremelanotide is off-label.
🔬MC4R agonist mechanism
PT-141 targets melanocortin-4 receptors in the central nervous system, triggering sexual arousal pathways rather than genital vasodilation. This is why it works differently from PDE5 inhibitors like sildenafil. The mechanism requires intact neural signaling and central arousal capacity.
⚠️This is not a vasodilator
PT-141 will not produce erections on demand in men without sexual desire or arousal. The mechanism requires intact neural signaling, and approximately 28–34% of men in controlled trials did not achieve meaningful response. If your dysfunction is vascular rather than desire-based, this compound is unlikely to help.
Clinical Indication
Who It's Actually For
FDA-Approved
Premenopausal women with acquired, generalized HSDD
Approved IndicationOff-Label (Women)
Situational HSDD, post-menopausal, secondary to SSRI use, post-cancer
Supported Off-LabelOff-Label (Men)
Psychogenic ED, desire-phase dysfunction, adjunct to PDE5i
Limited EvidenceNot Indicated
Vasculogenic ED, hormonal hypogonadism, relationship/psychological-primary issues
Not Appropriate| Population | Description | Status |
|---|---|---|
| FDA-Approved | Premenopausal women with acquired, generalized HSDD, clinically diagnosed | Approved Indication |
| Off-Label (Women) | Situational HSDD, post-menopausal, secondary to SSRI use, post-cancer | Supported Off-Label |
| Off-Label (Men) | Psychogenic ED, desire-phase dysfunction, adjunct to PDE5i; limited evidence | Limited Evidence |
| Not Indicated | Vasculogenic ED, hormonal hypogonadism, relationship/psychological-primary issues | Not Appropriate |
Population
Description
Status
Population
Description
Status
Population
Description
Status
Population
Description
Status
⚠️The male evidence gap
Men are using this compound off-label without Phase 3 trial data supporting efficacy. The best available controlled data shows a 34% meaningful response rate in men. That means the majority of men in the controlled data did not respond meaningfully. PT-141 at VitalRx is available for men under an off-label prescribing framework, but realistic expectations require that acknowledgment.
Mechanism
How It Works
Bremelanotide crosses the blood-brain barrier and binds to melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system. This activates sexual arousal pathways at the central nervous system level, producing desire and arousal independent of peripheral vasodilation. This is a fundamentally different mechanism from PDE5 inhibitors.
🔬CNS mechanism — distinct from peripheral vasodilators
PDE5 inhibitors (sildenafil, tadalafil) increase blood flow to genital tissue. PT-141 activates arousal circuits in the brain. The two mechanisms are complementary, which is why stacking (Section 09) is clinically relevant. PT-141 addresses desire; PDE5i addresses blood flow. Neither addresses the other's function.
Pharmacokinetic timeline
Injection Window
Subcutaneous injection administered. Bremelanotide begins absorbing. No effect expected in this window. Users who expect immediate response are misunderstanding the pharmacokinetics.
Peak Plasma
Bremelanotide reaches peak plasma concentration. CNS activation begins. Most users report onset of desire or arousal awareness during this window.
Active Window
Primary efficacy window. The compound is actively stimulating MC4R in the CNS. Sexual activity during this period has the highest probability of compound-supported arousal response.
Clearance / Hyperpigmentation
Bremelanotide clears systemically. MC1R activation (melanin pathway) may produce subtle skin darkening at injection site or face/gums with repeated dosing. Not universal at clinical doses.
Clinical Honesty
Realistic Expectations
⚠️The first dose is commonly the strongest
The first dose is commonly the most powerful due to tachyphylaxis, a rapid pharmacological accommodation that is distinct from classical tolerance. If you experience a dramatic response on dose one, that response level will not be stable. Subsequent doses produce a modulated, less intense version of the initial effect. This is normal pharmacology, not compound failure.
First 2–4 uses
Dose: 500 mcg
Expected: Strongest subjective response; highest nausea risk; calibration period
Caveat: Response will moderate — not compound failure
Ongoing protocol
Dose: 1.0–1.75 mg
Expected: Stable, moderate arousal enhancement; nausea typically diminishes
Caveat: 2× per week max; 72+ hr between uses
Maximum dose
Dose: 1.75 mg
Expected: FDA-established ceiling from Vyleesi trials
Caveat: Do not exceed; higher doses increase nausea and hyperpigmentation without proportional efficacy gain
| Phase | Dose | Expected Effect | Caveat |
|---|---|---|---|
| First 2–4 uses | 500 mcg | Strongest subjective response; highest nausea risk; calibration period | Response will moderate, not compound failure |
| Ongoing protocol | 1.0–1.75 mg | Stable, moderate arousal enhancement; nausea typically diminishes | 2× per week max; 72+ hr between uses |
| Maximum dose | 1.75 mg | FDA-established ceiling from Vyleesi trials | Higher doses increase nausea and hyperpigmentation without proportional efficacy gain |
Phase
Dose
Expected Effect
Caveat
Phase
Dose
Expected Effect
Caveat
Phase
Dose
Expected Effect
Caveat
⚡Blood pressure elevation
Average systolic BP increase of 6 mmHg in trials. This is clinically significant if you take antihypertensives, have hypertension, or use nitrates. The absolute contraindication is concurrent nitrate use (12-hour minimum separation required). Your VitalRx physician evaluates cardiovascular risk before prescribing.
Administration
Dosing Protocol
⚡SYRINGE MATH — #1 Dosing Error
Vials are typically supplied at 10 mg/mL concentration. A standard insulin syringe marked in "units" has 100 units = 1 mL. A dose of 500 mcg = 0.05 mL = 5 units on an insulin syringe. Never draw in milligrams. Your VitalRx vial label shows your dose in mL.
Titration (first 2–4 uses)
Dose: 500 mcg
Volume (10mg/mL): 0.05 mL (5 units)
Timing: 1–3 hr before activity
Frequency: Max 2×/week
Standard protocol
Dose: 1.0–1.5 mg
Volume (10mg/mL): 0.10–0.15 mL
Timing: 1–3 hr before activity
Frequency: Max 2×/week, 72 hr rest
Maximum dose
Dose: 1.75 mg
Volume (10mg/mL): 0.175 mL
Timing: 1–3 hr before activity
Frequency: Do not exceed
| Phase | Dose | Volume at 10mg/mL | Timing | Frequency |
|---|---|---|---|---|
| Titration (first 2–4 uses) | 500 mcg | 0.05 mL (5 units) | 1–3 hr before activity | Max 2×/week |
| Standard protocol | 1.0–1.5 mg | 0.10–0.15 mL | 1–3 hr before activity | Max 2×/week, 72 hr rest |
| Maximum dose | 1.75 mg | 0.175 mL | 1–3 hr before activity | Do not exceed |
Phase
Dose
Volume at 10mg/mL
Timing
Frequency
Phase
Dose
Volume at 10mg/mL
Timing
Frequency
Phase
Dose
Volume at 10mg/mL
Timing
Frequency
🔬Timing is the most common user error
Inject 1–3 hours before anticipated sexual activity. Onset is not immediate. Users who inject 15 minutes before and experience no effect have mistimed the dose, not failed to respond. Peak plasma concentration occurs at approximately 1–2 hours post-injection.
Tachyphylaxis
Cycling: Evidence vs. Myth
🔬What tachyphylaxis actually means
Tachyphylaxis is rapid MC4R receptor downregulation with repeated agonist exposure. It is distinct from classical tolerance. It is not dose-dependent and is not caused by building up "resistance." Rest periods restore receptor sensitivity. Dose escalation is not the correct response.
Maximum frequency
2 uses per week
Minimum rest between uses
72 hours
Monthly rest
1 week off after 3 weeks on
| Cycling Parameter | Recommendation |
|---|---|
| Maximum frequency | 2 uses per week |
| Minimum rest between uses | 72 hours |
| Monthly rest | 1 week off after 3 weeks on |
Cycling Parameter
Recommendation
Cycling Parameter
Recommendation
Cycling Parameter
Recommendation
"I take less than .5mg 2 or 3 times a week and I get a consistent boost — not the unnatural boost that many report at higher doses."
— ExcelMale forum, verified user
⚠️Hyperpigmentation warning
Darkening of face, gums, or breasts occurs in some users at higher doses or frequent use. It is not universal and is typically reversible after cessation, but may be slow to resolve. If it appears, reduce dose or discontinue. This is caused by MC1R activation (melanin pathway), a secondary receptor target of bremelanotide.
Getting Started
Ready to Inject
Physician Review
Cardiovascular history assessment, blood pressure baseline, medication screening for contraindications (nitrates, uncontrolled hypertension). This is not optional.
Pharmacy Fulfillment
503B registered compounding pharmacy. Medication labeled with your name, concentration, and dose in mL. Cold-chain shipped.
Storage
Refrigerate at 2–8°C. Protect from light. 30-day use window after reconstitution (pre-constituted VitalRx vials include specific batch instructions).
First Injection
500 mcg subcutaneous in abdomen or thigh. Administer 1–3 hours before anticipated activity. Do not use within 12 hours of nitrate medications.
Record Response
Note time of injection, dose, effect onset, nausea level (0–10 scale), and blood pressure if monitored. This data enables protocol optimization with your physician.
Protocol Optimization
Getting the Most From Your Protocol
PT-141 does not require routine lab monitoring. The compound does not affect testosterone, estrogen, IGF-1, glucose, or thyroid function. Optional cardiovascular baseline (resting BP, 12-lead ECG) is recommended for men with cardiac risk factors.
Timing as the primary variable
The single most impactful protocol adjustment is injection timing. Peak plasma occurs at 1–2 hours. The active efficacy window extends to approximately 4 hours post-injection. Users who report "PT-141 doesn't work" have frequently injected too close to activity or too far in advance.
Nausea management
Ondansetron (Zofran) 4 mg oral 30 minutes before injection if nausea is dose-limiting. Available by prescription. Ginger supplementation (1g) as a non-prescription alternative. Starting at 500 mcg rather than 1.75 mg for the first 2–4 uses substantially reduces initial nausea severity.
"My mistake was using it like Viagra — expecting it 15 minutes before. When I moved the shot to 2 hours earlier, completely different experience. The timing window is real."
— Reddit r/Peptides
Blood pressure awareness
Monitor blood pressure during the first 2–3 uses if you have any cardiovascular history. The average 6 mmHg systolic increase from trials is an average; individual variation exists. If you experience headache, flushing, or dizziness, measure BP and contact your VitalRx provider before the next dose.
Combination Protocols
Stacking
PT-141 + PDE5 Inhibitor (Sildenafil/Tadalafil)
Rationale: Central arousal (PT-141) + peripheral vasodilation (PDE5i). Complementary mechanisms addressing different phases of sexual response.
Consideration: Additive blood pressure effect. Requires cardiovascular evaluation.
Evidence: Clinical case data supports efficacy. No Phase 3 combination trial.
PT-141 + Oxytocin (Intranasal)
Rationale: Arousal enhancement (PT-141) + bonding/context enhancement (oxytocin). Different mechanism targets.
Consideration: Oxytocin non-responder rate 40–60%.
Evidence: Emerging. No controlled trial data for the combination.
⚠️No combination protocol has Phase 3 data
Stacking is off-label on top of off-label. VitalRx physicians evaluate stacking requests individually based on cardiovascular profile and individual response history. Do not combine these compounds without physician evaluation.
Cost & Access
Pricing
Gray Market (no Rx)
$35–$90/vial
No physician oversight. No lab verification. No dose labeling. Compounding source unknown.
Unknown PurityVyleesi Brand (FDA autoinjector)
$225–$290/dose
Covered by some insurance. Fixed 1.75mg dose. No titration possible.
FDA-ApprovedOther Medical Clinics
$299–$450+/mo
Varies significantly. Often excludes physician fee or pharmacy cost.
Variable⭐ VitalRx — Month 1
$249
Medication (titration supply), physician intake + prescription, supplies + shipping
503B Registered⭐ VitalRx — Month 2+
$179/mo
Ongoing medication supply, physician check-in, supplies + shipping
503B Registered| Source | Cost | Includes | Quality |
|---|---|---|---|
| Gray Market (no Rx) | $35–$90/vial | No physician, no labs, no dose labeling | Unknown Purity |
| Vyleesi Brand | $225–$290/dose | FDA-approved autoinjector. Fixed 1.75mg. No titration. | FDA-Approved |
| Other Medical Clinics | $299–$450+/mo | Varies. Often excludes physician or pharmacy cost. | Variable |
| ⭐ VitalRx — Month 1 | $249 | Medication, physician intake, prescription, supplies, shipping | 503B Registered |
| ⭐ VitalRx — Month 2+ | $179/mo | Ongoing medication, physician check-in, supplies, shipping | 503B Registered |
Source
Cost
Includes
Quality
Source
Cost
Includes
Quality
Source
Cost
Includes
Quality
Source
Cost
Includes
Quality
Source
Cost
Includes
Quality
Medication
Compounded bremelanotide from 503B registered pharmacy. Titration-compatible concentration.
Physician
Licensed physician evaluation, prescription, and ongoing protocol management.
Labs
Not required for PT-141. No routine bloodwork needed. Optional cardiovascular baseline.
Supplies + Shipping
Syringes, alcohol swabs, cold-chain packaging. Delivered to your door.
Regulatory Status
Legal Access in All 50 States
⚠️PT-141 is NOT on the FDA Category 2 list
PT-141 (bremelanotide) is not the same legal status as BPC-157 or CJC-1295. It was not banned in the December 2024 PCAC recommendations. The reason is specific: Vyleesi's 2019 FDA approval creates a different regulatory pathway that permits compounding under established legal frameworks.
Three-layer legal framework
Layer 1: The approved drug. Vyleesi (bremelanotide 1.75mg autoinjector) is FDA-approved for premenopausal women with HSDD. This established bremelanotide as a known pharmaceutical entity with a completed safety review.
Layer 2: Compounding for non-covered indications. 503A and 503B compounding pharmacies can compound bremelanotide at different concentrations and in injectable vial format under valid physician prescription. This enables dose titration and off-label male use.
Layer 3: Off-label prescribing framework. A physician may legally prescribe an approved drug for an unapproved indication. Approximately 21% of all US prescriptions are off-label. Male use of bremelanotide falls under this established legal framework.
503A Compounding
State board regulated
503B Registered
FDA cGMP inspected
Off-Label Rx
Physician-prescribed
Not Controlled
Not a scheduled substance
💊VitalRx regulatory compliance
Physician review before every prescription. Dose labeled in mL (not units requiring math). Tachyphylaxis monitored with structured rest periods. Non-responders evaluated by physician rather than escalated automatically. Cardiovascular contraindications screened at intake.
Real Questions
Community Q&A
How This Works
The VitalRx Model
Physician-Supervised
Licensed physicians review history before prescribing. Not a subscription box. Not a questionnaire that auto-approves.
503B Pharmacy
Medications from registered compounding pharmacies with quality testing and labeled doses. Not gray market.
Protocol Management
Ongoing check-ins, dose adjustments, tachyphylaxis management. Not a one-and-done prescription.
All 50 States
Telemedicine prescribing available nationally under physician supervision.
🧬Why VitalRx exists
VitalRx does not prescribe peptides to everyone who requests them. Physician review includes contraindication screening. Not every compound is appropriate for every patient, and that determination requires a licensed physician — not an intake form.
VitalRx exists because the peptide space has a physician problem. The gray market operates without cardiovascular screening. The academic literature exists in papers most patients cannot parse. The community forums are full of people dosing off YouTube guides. We built VitalRx to close that gap.
Physician-supervised · 503B quality · All 50 states